289 related articles for article (PubMed ID: 35361996)
1. Inferring gene expression from cell-free DNA fragmentation profiles.
Esfahani MS; Hamilton EG; Mehrmohamadi M; Nabet BY; Alig SK; King DA; Steen CB; Macaulay CW; Schultz A; Nesselbush MC; Soo J; Schroers-Martin JG; Chen B; Binkley MS; Stehr H; Chabon JJ; Sworder BJ; Hui AB; Frank MJ; Moding EJ; Liu CL; Newman AM; Isbell JM; Rudin CM; Li BT; Kurtz DM; Diehn M; Alizadeh AA
Nat Biotechnol; 2022 Apr; 40(4):585-597. PubMed ID: 35361996
[TBL] [Abstract][Full Text] [Related]
2. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
5. Identifying the tissues-of-origin of circulating cell-free DNAs is a promising way in noninvasive diagnostics.
Peng X; Li HD; Wu FX; Wang J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32427285
[TBL] [Abstract][Full Text] [Related]
6. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
7. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
8. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
9. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
11. Epigenetic analysis of cell-free DNA by fragmentomic profiling.
Zhou Q; Kang G; Jiang P; Qiao R; Lam WKJ; Yu SCY; Ma ML; Ji L; Cheng SH; Gai W; Peng W; Shang H; Chan RWY; Chan SL; Wong GLH; Hiraki LT; Volpi S; Wong VWS; Wong J; Chiu RWK; Chan KCA; Lo YMD
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2209852119. PubMed ID: 36288287
[TBL] [Abstract][Full Text] [Related]
12. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
13. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.
Lasseter K; Nassar AH; Hamieh L; Berchuck JE; Nuzzo PV; Korthauer K; Shinagare AB; Ogorek B; McKay R; Thorner AR; Lee GM; Braun DA; Bhatt RS; Freedman M; Choueiri TK; Kwiatkowski DJ
Genet Med; 2020 Aug; 22(8):1366-1373. PubMed ID: 32341571
[TBL] [Abstract][Full Text] [Related]
15. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA.
Shen SY; Burgener JM; Bratman SV; De Carvalho DD
Nat Protoc; 2019 Oct; 14(10):2749-2780. PubMed ID: 31471598
[TBL] [Abstract][Full Text] [Related]
16. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
17. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation.
Ivanov M; Baranova A; Butler T; Spellman P; Mileyko V
BMC Genomics; 2015; 16 Suppl 13(Suppl 13):S1. PubMed ID: 26693644
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden.
Zhu G; Guo YA; Ho D; Poon P; Poh ZW; Wong PM; Gan A; Chang MM; Kleftogiannis D; Lau YT; Tay B; Lim WJ; Chua C; Tan TJ; Koo SL; Chong DQ; Yap YS; Tan I; Ng S; Skanderup AJ
Nat Commun; 2021 Apr; 12(1):2229. PubMed ID: 33850132
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
